Leben mit Rheuma: Rehabilitation und adjuvante Therapien

Zusammenfassung

Die Entwicklung neuer zielgerichteter medikamentöser Therapien hat zu einer deutlichen Verbesserung der Behandlung der akuten Entzündungsaktivität geführt. Die größere Herausforderung stellt im Alltag oftmals jedoch der Umgang mit bereits eingetretenen Behinderungen und Schmerzen dar. Hierfür gibt es zahlreiche adjuvante Möglichkeiten, deren Stellenwert im Beitrag erörtert wird.

Abstract

Novel targeted therapies have successfully reduced the acute inflammatory activity of rheumatic diseases. However, existing functional incapacities and disabilities are often more challenging in daily routine practice. To treat these, there are numerous adjuvant therapeutic approaches, whose significance is discussed in the following article.

Schlüsselwörter

Rehabilitation - Phytopharmaka - adjuvante Therapie

Key words

rehabilitation - adjuvant therapy - phytopharmaceuticals

• Literatur

• 1 Mau W, Beyer W, Ehlebracht-König I. et al. Treat to Participation. Zeitschrift für Rheumatologie 2015; 74: 553-557
• 2 Alvarez-Hernandez E, Cesar Casasola-Vargas J, Lino-Perez L. et al. Complementary and alternative medicine in patients attending a rheumatology department for the first time. Analysis of 800 patients. Reumatol Clin 2006; 2: 183-189
• 3 Schneider M, LM Abholz HH et al. Management der frühen rheumatoiden Arthritis – Interdisziplinäre S3-Leitlinie. 2011; Klinische Leitlinie im Auftrag der Deutschen Gesellschaft für Rheumatologie. Available from: https://dgrh.de/dam/jcr:b5dea1ff-4643-46b2-bff0-be-9d7593075e/7_komplementaere_verfahren_ra.pdf
• 4 Al-Yasiry ARM, Kiczorowska B. Frankincense–therapeutic properties. Postepy Hig Med Dosw (online) 2016; 70: 380-391
• 5 Ammon HPT. Boswelliasäuren (Inhaltsstoffe des Weihrauchs)als wirksame Prinzipien zur Behandlung chronisch entzündlicher Erkrankungen*. Wiener Medizinische Wochenschrift 2002; 152: 373-378
• 6 Ammon HPT. Boswellic Acids and Their Role in Chronic Inflammatory Diseases, in Anti-inflammatory Nutraceuticals and Chronic Diseases. Gupta SC, Prasad S, Aggarwal BB. Editors. Springer International Publishing: Cham. 2016: 291-327
• 7 Yousefi B, Jadidi-Niaragh F, Azizi G. et al. The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Modern Rheumatology 2013; 1-14
• 8 Ernst E. Frankincense: Systematic review. BMJ: British Medical Journal 2008; 337.
• 9 Butterweck V. Mechanism of Action of St John’s Wort in Depression. CNS Drugs 2003; 17: 539-562
• 10 Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Pharmacology 2013; 4: 177
• 11 Schmidt M, Butterweck V. The mechanisms of action of St. John’s wort: an update. Wiener Medizinische Wochenschrift 2015; 165: 229-235
• 12 Galeotti N. Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions. Journal of Ethnopharmacology 2017; 200: 136-146
• 13 Brendler T, Gruenwald J, Ulbricht C. et al. Devil’s Claw (Harpagophytum procumbens DC). Journal of Herbal Pharmacotherapy 2006; 6: 89-126
• 14 Sticher O, Heilmann J, Zündorf I. Hänsel/ Sticher Pharmakognosie Phytopharmazie. 2015: Wissenschaftliche
• 15 Grant L, McBean DE. Fyfe L. et al. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytotherapy Research 2007; 21: 199-209
• 16 Haseeb A, Ansari MY, Haqqi TM. Harpagoside suppresses IL-6 expression in primary human osteoarthritis chondrocytes. Journal of Orthopaedic Research 2017; 35: 311-320
• 17 Fiebich BL, Muñoz E, Rose T. et al. Molecular Targets of the Antiinflammatory Harpagophytum procumbens (Devil's claw): Inhibition of TNFα and COX-2 Gene Expression by Preventing Activation of AP-1. Phytotherapy Research 2012; 26: 806-811
• 18 Warnock M, McBean D, Suter A. et al. Effectiveness and safety of Devil's Claw tablets in patients with general rheumatic disorders. Phytotherapy Research 2007; 21: 1228-1233
• 19 Chantre P, Cappelaere A, Leblan D. et al. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine 2000; 7: 177-183
• 20 Frerick H, Biller A, Schmidt U. A treatment schedule for coxarthrosis: A double-blind study with Devil's claw Stufenschema bei coxarthrose: Doppelblindstudie mit Teufelskralle. 2001; 5: 34-41
• 21 Schmidt TJ, Willuhn G, Steigel A. et al. Sesquiterpene Lactones and Inositol Esters from Arnica angustifolia1,*. Planta Med 1995; 61: 544-550
• 22 Merfort I. Arnika: Neue Erkenntnisse zum Wirkungsmechanismus einer traditionellen Heilpflanze. Complementary Medicine Research 2003; 10 (Suppl. 01) 45-48
• 23 Dragos D, Gilca M, Gaman L. et al. Phytomedicine in Joint Disorders. Nutrients 2017; 9: 70
• 24 Nahrstedt A, Schmidt M, Jäggi R. et al. Willow bark extract: The contribution of polyphenols to the overall effect. Wiener Medizinische Wochenschrift 2007; 157: 348-351
• 25 Wegener T. Zur Studienlage von Weidenrindenextrakten. Vol. 30. 2009
• 26 Biegert C, Wagner I, Ludtke R. et al. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials. J Rheumatol 2004; 31: 2121-2130
• 27 Products, C.o.H.M. Community Herbal Monograph on Salix, cortex. 2017; Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/herbal/medicines/herbal_med_000072.jsp&mid = WC0b01ac058001fa1d#
• 28 Vlachojannis JE, Cameron M, Chrubasik S. A systematic review on the effectiveness of willow bark for musculoskeletal pain. Phytother Res 2009; 23: 897-900
• 29 Cheung JM, Scarsbrook D, Klinkhoff AV. Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics. The Journal of Rheumatology 2012; 39: 716-719
• 30 Wassenberg S. Parenterale Goldtherapie bei rheumatoider Arthritis – pro. Dtsch med Wochenschr 2011; 136: 1676-1676
• 31 Svensson Å, Möller H, Björkner B. et al. Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines. BMC Dermatology 2002; 2: 2-2
• 32 Bendix G, Bjelle A. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 1996; 55: 169-176
• 33 Smolen J, Landewé R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases 2017; 0: 1-18